Stocks Health care MXCT
NASDAQ · Health careMaxcyte, Inc. (MXCT)
Maxcyte, Inc. brought in $31.1M of revenue over the twelve months to June 30, 2026, down 13.2% from a year earlier. It posted a net loss of $35.6M. In fiscal 2025 capital spending exceeded operating cash flow by $36.2M. At June 30, 2026 it held $15M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
What Maxcyte, Inc. does
Maxcyte, Inc. is registered with the SEC under industry code SIC 8731 (Services-Commercial Physical & Biological Research). Its shares trade on NASDAQ under the ticker MXCT.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $33M | -$44.6M | -$0.42 | -$36.2M |
| 2024 | $38.6M | -$41.1M | -$0.39 | -$29.3M |
| 2023 | $41.3M | -$37.9M | -$0.37 | -$25.4M |
| 2022 | $44.3M | -$23.6M | -$0.23 | -$33.3M |
| 2021 | $33.9M | -$19.1M | -$0.21 | -$14.5M |
| 2021 | $26.2M | -$11.8M | -$0.17 | -$10.9M |
Latest SEC filings
What Maxcyte, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 13, 2026Quarterly report 10-Q · period to June 30, 2026
- August 12, 2026
- August 4, 2026Activist stake (5% or more) SCHEDULE 13D
- July 29, 2026Passive stake changed SCHEDULE 13G/A
- June 17, 2026
- June 16, 2026
- May 14, 2026Activist stake (5% or more) SCHEDULE 13D
- May 13, 2026Quarterly report 10-Q · period to March 31, 2026
- May 12, 2026
- April 29, 2026
Questions about MXCT
What does Maxcyte, Inc. do?
Maxcyte, Inc. is registered with the SEC under industry code SIC 8731 (Services-Commercial Physical & Biological Research). Its shares trade on NASDAQ under the ticker MXCT.
Is Maxcyte, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $35.6M on revenue of $31.1M.
How much revenue does Maxcyte, Inc. make?
Over the twelve months to June 30, 2026 Maxcyte, Inc. reported revenue of $31.1M. That is 13.2% less than a year earlier.
When did Maxcyte, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026.
Similar companies
Follow MXCT
Get an email when Maxcyte, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow MXCT: get an email when it filesWhere the numbers come from
Financial figures are the values Maxcyte, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.